Finally, our findings here could highlight a potential personalised treatment for a subset of patients who, upon biopsy are found to have tumours expressing high c‐Met but low βIII‐tubulin and may therefore benefit from Amuvatinib. This evidence concerns the gene MET and neoplasm.